AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
Kidney Cancer: Conflicting Adjuvant Immunotherapy Data and a Real Option for Non-Clear Cell Disease
By Benjamin A. Teply, MD
We have yet to have truly confirmatory data for a benefit for adjuvant immunotherapy in kidney cancer.
Kidney Cancer: Conflicting Adjuvant Immunotherapy Data and a Real Option for Non-Clear Cell Disease
By Benjamin A. Teply, MD
We have yet to have truly confirmatory data for a benefit for adjuvant immunotherapy in kidney cancer.
Kidney Cancer: Conflicting Adjuvant Immunotherapy Data and a Real Option for Non-Clear Cell Disease
By Benjamin A. Teply, MD
We have yet to have truly confirmatory data for a benefit for adjuvant immunotherapy in kidney cancer.
Rethinking Frontline Therapy in Leukemia: Why Lower-Intensity Regimens Are Gaining Ground in AML, MDS, and ALL
By Anand Ashwin Patel, MD
Newer data are steadily narrowing the population that benefits from intensive chemotherapy in acute leukemia.
Rethinking Frontline Therapy in Leukemia: Why Lower-Intensity Regimens Are Gaining Ground in AML, MDS, and ALL
By Anand Ashwin Patel, MD
Newer data are steadily narrowing the population that benefits from intensive chemotherapy in acute leukemia.
Rethinking Frontline Therapy in Leukemia: Why Lower-Intensity Regimens Are Gaining Ground in AML, MDS, and ALL
By Anand Ashwin Patel, MD
Newer data are steadily narrowing the population that benefits from intensive chemotherapy in acute leukemia.
Gastrointestinal Cancer Updates From the Best of GI Oncology 2026
By Haadi Ali, MD ; Ibrahim Halil Sahin, MD
Daraxonrasib is an orally administered, multiselective RAS(ON) inhibitor designed to target the active, GTP-bound state of multiple mutant and wild-type RAS proteins.
Gastrointestinal Cancer Updates From the Best of GI Oncology 2026
By Haadi Ali, MD ; Ibrahim Halil Sahin, MD
Daraxonrasib is an orally administered, multiselective RAS(ON) inhibitor designed to target the active, GTP-bound state of multiple mutant and wild-type RAS proteins.
Gastrointestinal Cancer Updates From the Best of GI Oncology 2026
By Haadi Ali, MD ; Ibrahim Halil Sahin, MD
Daraxonrasib is an orally administered, multiselective RAS(ON) inhibitor designed to target the active, GTP-bound state of multiple mutant and wild-type RAS proteins.
A New Antibody-Drug Conjugate and a Biomarker Reality Check for Small Cell Lung Cancer
By Mark Alan Klein, MD
Small cell lung cancer has trailed its non-small cell counterpart in new drug approvals for years, and at this year's ASCO meeting there were no studies presented that affect first-line treatments at this time.
A New Antibody-Drug Conjugate and a Biomarker Reality Check for Small Cell Lung Cancer
By Mark Alan Klein, MD
Small cell lung cancer has trailed its non-small cell counterpart in new drug approvals for years, and at this year's ASCO meeting there were no studies presented that affect first-line treatments at this time.
A New Antibody-Drug Conjugate and a Biomarker Reality Check for Small Cell Lung Cancer
By Mark Alan Klein, MD
Small cell lung cancer has trailed its non-small cell counterpart in new drug approvals for years, and at this year's ASCO meeting there were no studies presented that affect first-line treatments at this time.
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
CAR-T Cell Therapy and Bispecific Antibodies Are Transforming Acute Lymphoblastic Leukemia
By Thomas Knight, MD
Ten years ago, ALL was a chemotherapy-heavy disease with poor long-term survival for many patient groups. That has changed dramatically.
CAR-T Cell Therapy and Bispecific Antibodies Are Transforming Acute Lymphoblastic Leukemia
By Thomas Knight, MD
Ten years ago, ALL was a chemotherapy-heavy disease with poor long-term survival for many patient groups. That has changed dramatically.
CAR-T Cell Therapy and Bispecific Antibodies Are Transforming Acute Lymphoblastic Leukemia
By Thomas Knight, MD
Ten years ago, ALL was a chemotherapy-heavy disease with poor long-term survival for many patient groups. That has changed dramatically.
Next-Generation Cellular and T-Cell Engaging Therapies Are Reshaping Multiple Myeloma Care
By Cindy Varga, MD
Multiple myeloma treatment is shifting toward earlier CAR-T use, dual-antigen bispecifics, and next-gen platforms (allogeneic, in vivo, mRNA) to expand global access.
Next-Generation Cellular and T-Cell Engaging Therapies Are Reshaping Multiple Myeloma Care
By Cindy Varga, MD
Multiple myeloma treatment is shifting toward earlier CAR-T use, dual-antigen bispecifics, and next-gen platforms (allogeneic, in vivo, mRNA) to expand global access.
Next-Generation Cellular and T-Cell Engaging Therapies Are Reshaping Multiple Myeloma Care
By Cindy Varga, MD
Multiple myeloma treatment is shifting toward earlier CAR-T use, dual-antigen bispecifics, and next-gen platforms (allogeneic, in vivo, mRNA) to expand global access.
Prostate Cancer in 2026: Perioperative Therapy, Biomarker-Driven Combinations, and Pausing Treatment
By Peter Silberstein, MD
Four developments from this year's ASCO meeting reshape decision-making across the prostate cancer spectrum, from the operating room to the metastatic setting.
Prostate Cancer in 2026: Perioperative Therapy, Biomarker-Driven Combinations, and Pausing Treatment
By Peter Silberstein, MD
Four developments from this year's ASCO meeting reshape decision-making across the prostate cancer spectrum, from the operating room to the metastatic setting.
Prostate Cancer in 2026: Perioperative Therapy, Biomarker-Driven Combinations, and Pausing Treatment
By Peter Silberstein, MD
Four developments from this year's ASCO meeting reshape decision-making across the prostate cancer spectrum, from the operating room to the metastatic setting.
CAR-T Cell Therapy for Large B-Cell Lymphoma: Who, When, and Where to Deliver It
By Chenyu Lin, MD
CAR-T cell therapy for large B-cell lymphoma is expanding through broader patient eligibility, earlier treatment, head-to-head trials, and remote monitoring.
CAR-T Cell Therapy for Large B-Cell Lymphoma: Who, When, and Where to Deliver It
By Chenyu Lin, MD
CAR-T cell therapy for large B-cell lymphoma is expanding through broader patient eligibility, earlier treatment, head-to-head trials, and remote monitoring.
CAR-T Cell Therapy for Large B-Cell Lymphoma: Who, When, and Where to Deliver It
By Chenyu Lin, MD
CAR-T cell therapy for large B-cell lymphoma is expanding through broader patient eligibility, earlier treatment, head-to-head trials, and remote monitoring.
Pancreatic Cancer: A RAS Inhibitor Nearly Doubles Survival, and a KRAS Vaccine Shows Real Promise
By Weijing Sun, MD
Pancreatic cancer has been a difficult disease to move the needle on: median survival with first-line chemotherapy has hovered around six months for decades, and targeted therapy has largely unsuccess here despite working elsewhere.
Pancreatic Cancer: A RAS Inhibitor Nearly Doubles Survival, and a KRAS Vaccine Shows Real Promise
By Weijing Sun, MD
Pancreatic cancer has been a difficult disease to move the needle on: median survival with first-line chemotherapy has hovered around six months for decades, and targeted therapy has largely unsuccess here despite working elsewhere.
Pancreatic Cancer: A RAS Inhibitor Nearly Doubles Survival, and a KRAS Vaccine Shows Real Promise
By Weijing Sun, MD
Pancreatic cancer has been a difficult disease to move the needle on: median survival with first-line chemotherapy has hovered around six months for decades, and targeted therapy has largely unsuccess here despite working elsewhere.